Processing

Please wait...

Settings

Settings

Goto Application

1. US6706729 - Thiolesters and uses thereof

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

What is claimed is:

1. A compound having the formula:

(MOL) (CDX)   wherein:
R 1 is Y-Z;
Y is —(CH 2) m—, wherein m is an integer from 1 to 6;
Z is pyridinio having the structure:

(MOL) (CDX)  
wherein
R 12, R 13, R 14, R 15, and R 16, are members independently selected from the group consisting of H—, C(═O)NH 2, and substituted carboxamide groups;
R 2 is selected from the group consisting of H, CH 3, C(═O)NH 2 and C(═O)OCH 3 groups;
R 3, R 4 and R 5 are members independently selected from the group consisting of H, a halogen, NO 2, C(═O)ONH 2, and C(═O)OCH 3 groups;
R 6 is selected from the group consisting of H, alkyl, CH 3, substituted alkyl, aryl, substituted aryl, and arylalkyl groups;
R 7, R 8, R 10 and R 11 are H;
R 9 is (O═S═O)—G′ wherein G′ is selected from the group consisting of —NH 2, —NH-alkyl, —NH-acyl groups, nitroaryl, and aryl-NH-acyl.
 
2. The compound of claim 1, wherein m is the integer 4.
 
3. A method for inactivating a virus, said method comprising contacting said virus with a compound of claim 1, wherein contacting said virus with said compound inactivates said virus.
 
4. The method of claim 3, wherein the compound dissociates a zinc ion from a zinc finger.
 
5. The method of claim 3, wherein said virus is a retrovirus derived from a avian sarcoma and leukosis retroviral group, a mammalian B-type retroviral group, a human T cell leukemia and bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group, or a lentivirus group.
 
6. The method of claim 5, wherein said retrovirus is an HIV-1, an HIV-2, an SIV, a BIV, an EIAV, a Visna, a CaEV, an HTLV-1, a BLV, an MPMV, an MMTV, an RSV, an MuLV, a FeLV, a BaEV, or an SSV retrovirus.
 
7. The method of claim 6, wherein said virus is an HIV-1 retrovirus.
 
8. The method of claim 3, wherein the contacting of said virus with said compound is performed in vivo.
 
9. The method of claim 8, wherein said compound is administered to an animal as a veterinary pharmaceutical formulation.
 
10. The method of claim 3, wherein the contacting of said retrovirus with said compound is performed in vitro.
 
11. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable adjuvant.